DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study

Lancet

Volumn 360, Issue 9343, 2002, Pages 1381-1391

  Barratt, P L ^a   Seymour, M T ^b   Stenning, S P ^c   Georgiades, I ^d   Walker, C ^d   Birbeck, K ^d   Quirke, P ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MARKER; FLUOROURACIL; FORMALDEHYDE; PARAFFIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PORTAL VEIN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0037010411     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11402-4     Document Type: Article

References (38)

1. UK Department of Health. Guidance on commissioning cancer services: improving outcomes in colorectal cancer, the research evidence. 1997;86-97 Department of Health, London.
2. Marmounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03 and C-04). J Clin Oncol. 17:1999;1349-1355.
3. IMPACT B2 investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 17:1999;1356-1363.
4. Hayes D.F., Trock B., Harris A.L. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat. 52:1998;305-319.
5. Hayes D.F., Bast R.C., Desch C.E., et al. Tumour marker utility grading system: a framework to evaluate clinical utility of tumour markers. J Natl Cancer Inst. 88:1996;1456-1466.
6. AXIS Steering Group. The AXIS colorectal cancer trial: randomization of over 2000 patients. Br J Surg. 81:1994;1672.
7. James RD. Intraportal 5FU (PVI) and peri-operative radiotherapy (RT) in the adjuvant treatment of colorectal cancer (CRCa): 3681 Patients randomised in the UK coordinating committee on cancer research (UKCCCR) AXIS trial. Proc Am Soc Clin Oncol 1999; 18: 264a (abstr).
8. Laurent Puig P., Olschwang S., Delattre O., et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology. 102:1992;1136-1141.
9. Jen J., Kim H.G., Piantadosi S., et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 331:1994;213-221.
10. Zhou W., Goodman S.N., Galizia G., et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet. 359:2002;219-225.
11. Ahnen D.J., Feigl P., Quan G., et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 58:1998;1149-1158.
12. Arango D., Corner G.A., Wadler S., Catalano P.J., Augenlicht L.H. C-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res. 61:2001;4910-4915.
13. Halling K.C., French A.J., McDonnell S.K., et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancer. J Natl Cancer Inst. 91:1999;1295-1303.
14. Aebi S., Fink D., Gordon R., et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 3:1997;1763-1767.
15. Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 355:2000;1745-1750.
16. Risques R.-A., Moreno V., Marcuello E., et al. Redefining the significance of aneuploidy in the prognostic assessment of colorectal cancer. Lab Invest. 81:2001;307-315.
17. Bast R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumour markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 19:2001;1865-1878.
18. Spiro L., Joslyn G., Nelson L., Leppert M., White R. A CA repeat 30-70 KB downstream from the adenomatous polyposis coli (APC) gene. Nucleic Acids Res. 19:1991;6348.
19. Cawkwell L., Bell S.M., Lewis F.A., Dixon M.F., Taylor G.R., Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer. 67:1993;1262-1267.
20. Vogelstein B., Fearon E.R., Kern S.E., et al. Allelotype of colorectal carcinomas. Science. 244:1989;207-211.
21. Muleris M., Salmon R.-J., Dutrillaux B. Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet. 46:1990;143-156.
22. Bardi G., Johansson B., Pandis N., et al. Cytogenetic aberrations in colorectal adenocarcinomas and their correlation with clinicopathologic features. Cancer. 71:1992;306-314.
23. Malkhosyan S., Yasuda J., Soto J.L., Sekiya T., Yokota J., Perucho M. Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting. Proc Natl Acad Sci USA. 95:1998;10170-10175.
24. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:1998;5248-5257.
25. Gonzalez-Garcia I., Moreno V., Navarro M., et al. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst. 92:2000;544-549.
26. Watanabe T., Wu T.T., Catalano P.J., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 344:2001;1196-1206.
27. Watatani M., Yoshida T., Kuroda K., Ieda S., Yasutomi M. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer. Cancer. 77:1996;1688-1693.
28. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 319:1988;525-532.
29. Salahshor S., Kressner U., Fischer H., et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer. 81:1999;190-193.
30. Carethers J.M., Hawn M.T., Greenson J.K., Hitchcock C.L., Boland C.R. Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer. Gastroenterology. 114:1998;1188-1195.
31. Soong R., Grieu F., Robbins P., et al. P53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res. 3:1997;1405-1411.
32. Bennett M.A., Kay E.W., Mulcahy H., et al. Ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma. J Clin Pathol. 48:1995;M310-M315.
33. Kern S.E., Fearon E.R., Tersmette K.W.F., et al. Allelic loss in colorectal-carcinoma. JAMA. 261:1989;3099-3103.
34. Carethers J.M., Chauhan D.P., Fink D., et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 117:1999;123-131.
35. Barratt P.L., Seymour M.T., Phillips R.M., Bibby M.C., Double J.A., Quirke P. The role of the DNA mismatch repair protein, hMLH-1 in sensitivity of colon cancer cells to chemotherapeutic agents used clinically. Br J Cancer. 78:1998;P9.
36. Augenlicht L.H., Wadler S., Corner G., et al. Low-level c-myc amplification in human colonic carcinoma cell lines and tumours: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res. 57:1997;1769-1775.
37. Arango D., Corner G.A., Wadler S., Catalano P.J., Augenlicht L.H. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res. 61:2001;4910-4915.
38. Edler D., Glimelius B., Hallstrom M., et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol. 20:2002;1721-1728.